NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ:OCUL) between March 10, 2016 and July 11, 2017. You are hereby notified that Levi & Korsinsky filed Kim v. Ocular Therapeutix, Inc., a securities class action lawsuit in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-sba/ocular-therapeutix-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Ocular Therapeutix you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



